In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Procyon enters into cancer technology option agreement
Procyon and Chiron not to extend license option
Procyon extends licence option agreement with Chiron
Procyon receives Canadian tumour patent
Procyon gains additional patent protection for cancer screening test
Transition Therapeutics enters into an exclusive option agreement with Novo Nordisk
Ceragenix Enters Into Second Exclusive Option to License Agreement for Antimicrobial Medical Device